Released Aug 5, 2020, after the close
10-Q filed Aug 6, 2020, 37 days after period end · 0001564590-20-036997
Q2 2020 · 10-Q
Revenue$9.47M$9.47M −10.0% vs Q2 2019+32.4% vs Q1 2020
Net Income$29.87M$29.87M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted$0.94$0.94 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$16,417,000N/M
Operating Cash Flowderived-$12,500,000N/M
Margins · derived
Operating margin-173.4%−43.4 pt vs Q2 2019
Net margin315.5%+446.5 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $9.47M | $10.53M | $5.70M | $15.36M |
| Net Income | $29.87M | -$13.79M | -$11.54M | -$1.81M |
| EPS Diluted | $0.94 | -$0.60 | -$24.17 | -$4.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR